Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal Of The National Comprehensive Cancer Network 2015, 13: 424-34. PMID: 25870379, PMCID: PMC8161684, DOI: 10.6004/jnccn.2015.0058.Peer-Reviewed Original ResearchConceptsMyeloproliferative neoplasmsClassical Philadelphia chromosome-negative myeloproliferative neoplasmsJAK1/JAK2 inhibitor ruxolitinibPrognostic scoring systemHematologists/oncologistsPhiladelphia chromosome-negative myeloproliferative neoplasmsJAK2 inhibitor ruxolitinibQuality of lifeCytoreductive agentsSymptom burdenVascular eventsInhibitor ruxolitinibPolycythemia veraDiagnostic criteriaEssential thrombocythemiaDisease pathogenesisFirst treatmentScoring systemNovel therapeuticsMyelofibrosisCALR mutationsMolecular diagnosisNeoplasms